The Clinical Trial Centre (CEC) performs clinical studies. CEC has dedicated facilities and updated ophthalmological equipment. Clinical patient-oriented research involves characterizing disease progression and testing new discoveries by carrying out carefully controlled research studies in patients, i. e., clinical trials. This includes testing not only new drugs, but also new methods, devices, imaging and surgical procedures as well as well-designed prospective, observational, longitudinal studies.
The Clinical Trial Centre (CEC) performs clinical studies. CEC has dedicated facilities and updated ophthalmological equipment. Clinical patient-oriented research involves characterizing disease progression and testing new discoveries by carrying out carefully controlled research studies in patients, i. e., clinical trials and other types of clinical studies. This includes testing not only new drugs, but also new methods, devices, imaging and surgical procedures as well as well-designed prospective, observational, longitudinal studies. Our research is focused in age-related eye diseases with special emphasis on diabetic retinopathy and age-related macular degeneration. CEC is certified as Clinical Site of Excellence by the EVICR.net – European Vision Institute Clinical Research Network (Clinical Site nº 1), that is a clinical trial centre in ophthalmology that complies with ICH GCP Guidelines with written SOPs. CEC has the necessary equipment and personnel to perform clinical trials and has proven expertise and scientific publications in this area.
Biomarkers of progression of Diabetic Retinopathy Vision Threatening Complications in Diabetic Retinopathy Progression Epidemiological characterization of AMD. Characterization of progression of AMD from intermediate to late forms of AMD Evaluation of novel treatment options for complications of Diabetic Retinopathy Validation Outcomes and testing treatments for sight threatening Age-Related Macular Degeneration
Retina: Identification of phenotypes and biomarkers of retinal disease progression Testing new methods of early diagnosis of macular edema and retinal vascular disease Characterisation of responders and non-responders to new available therapies of retinal disease Characterization of phenotypes of diabetic retinopathy Neurovascular degeneration in age-related disease Glaucoma: Evaluation of new drugs for glaucoma treatment Other: Optical Coherence Tomography in the diagnosis of neurological diseases Diagnostic correlations in imaging between brain and retina Eye fundus imaging as a predictor of systemic vascular disease Neurovascular degeneration in age-related disease
Inês Marques
André Coutinho
Andreia Rosa
Bruno Teixeira
Celso Costa
Conceição Lobo
Filipe Mira Ferreira
Inês Laíns
Inês Pereira Marques
Isabel Pires
João Figueira
João Pedro Marques
Joana Costa
Joaquim Neto Murta
José Costa
Lisa-Marie Anders
Luís Silva Pires
Maria Fonseca
Marco Marques
Maria João Quadrado
Maria Luísa Ribeiro
Maria Luz Cachulo
Pedro Faria
Philipp Anders
Raquel Félix
Rufino Silva
Filipe Martins
Inês Rego
Catarina Eloy
Filipe Martins
Marcela Pascoal
Sandra Cristina Pardal
Ana Almeida
Ana Nunes
Ana Rocha
Ana Rita Santos
Diana Ramos
Marta Lopes
Aida Cristina Vitorino
Eugénia Cardoso
Maria do Céu Simões
Paulo Marques
Tânia Mesquita
Joana Abrantes
Patrícia Barreto
Sandra Cristina Pardal
Patrícia Barreto
‣ Alcon
‣ Alimera
‣ Allergan
‣ Bausch & Lomb
‣ Bayer
‣ Chiltern
‣ Eurotrials
‣ EyeTech
‣ Farmalabor
‣ IRIS Pharma
‣ Lilly
‣ Merck Sharp & Dohme
‣ Novartis
‣ OM Pharma
‣ Pfizer
‣ Pharmaceutical Product Development
‣ Pharmacia Corporation
‣ Sanofi-Aventis
‣ Servier
‣ Théa